Blueprint Medicines, a Sanofi Company, Announces Four-Year PIONEER Data Showing Sustained Benefit and Long-Term Safety of AYVAKIT® (avapritinib) in Indolent Systemic Mastocytosis
— Real-world study of AYVAKIT highlights improvement across ISM symptoms — — 12 data presentations at 2026 AAAAI Annual Meeting reflect…
